To compare the clinical utility of the Recursive Partitioning Analysis (RPA) and Graded Prognostic Assessment (GPA) in predicting outcomes for moderate prognosis patients with brain metastases. Methods & materials: We reviewed 101 whole brain radiotherapy cases. RPA and GPA were calculated. Overall survival was compared. Results: Sixty-eight patients had moderate prognosis. RPA patient characteristics for increased death hazard were ≤10 WBRT fractions or no surgery/radiosurgery. GPA patients had increased death risk with no surgery/radiosurgery or lower Karnofsky Performance Status. conclusion: The indices have similar predicted survival. Patients scored by RPA with longer radiation schedules had longer survival; patients scored by GPA did not. This indicates GPA is more clinically useful, leaving less room for subjective treatment choices.
ReseaRch aRticle
Over 170,000 cases of brain metastases are diagnosed in the USA each year, and the length of survival for these patients is often limited [1] . The Radiation Therapy Oncology Group Recursive Partitioning Analysis (RPA) and Graded Prognostic Assessment (GPA) are prognostic indices validated to predict survival and guide treatment for these patients [2] [3] [4] [5] . These indices were formulated by comparing survival to patient characteristics compiled from brain metastasis treatment protocols across three decades.
The RPA has three classes of patients enumerated as 'I', 'II' and 'III,' with class I having the longest predicted survival and class III the shortest. The RPA classes are based upon age, Karnofsky performance status (KPS), control of the primary tumor and evidence of extracranial metastases (table 1) [2] . The GPA has four classes with a score that may be considered analogous to a student's grade point average in school. The classes are arranged from best to worst prognosis as follows: 3.5 to 4.0, 3.0, 1.5-2.5 and 0.0-1.0. The GPA employs criteria that are slightly different than those used in the RPA, estimating survival by age, performance status, number of brain metastases and extracranial metastases (table 2) [4] .
Treatment options for brain metastases include surgery, stereotactic radiosurgery (SRS), whole brain radiation therapy (WBRT), supportive measures or combinations of these modalities. The median survival (MS) of the worst prognosis patients is estimated by the RPA and GPA to be 2.3 and 2.6 months respectively [2, 4] . In these patients, treatments are usually less aggressive and typically include WBRT and/or steroids. The best fractionation scheme is not well established, but there are many who favor shorter courses or supportive care only [6] [7] [8] .
More aggressive treatment may produce better outcomes in good prognosis patients. There are data showing a survival advantage for patients with a single brain metastasis who receive surgery or SRS in addition to WBRT [9, 10] . A recently reported meta-analysis of randomized trials of SRS ± WBRT in RPA I or II patients with one to four brain metastases revealed that, in patients ≤50 years old, survival was significantly better with SRS alone [11] . This is currently not the standard of care [12, 13] , but may affect future guidelines.
With 'moderate prognosis' patients (RPA II or GPA 1.5-2.5), treatment options become more variable. For these patients, the MS is 4.2 months for RPA II and 3.8 months for GPA 1.5-2.5 patients. Selecting the best treatment for patients in these categories is challenging, and there have been changes suggested to both the GPA and RPA to add more granularity. Specifically, Sperduto et al. have created the 'Diagnosis Specific-GPA' (DS-GPA) where the GPA score is adjusted based on the primary disease histology [5] . Similarly, Yamamoto et al. have published recommendations to subdivide the RPA II into three subgroups that represent the range of MS lengths within this group [14] .
In our clinic, moderate prognosis patients who are expected to have more favorable outcomes based on their initial presentation will frequently receive more aggressive treatment for their brain metastases such as protracted WBRT regimens (generally 35-37.5 Gy in 14-15 fractions) with or without surgery or SRS. We were interested in evaluating the median survival in the patients who had moderate prognosis (RPA II or GPA 1.5-2.5). The objective of this study was to evaluate whether either the GPA or the RPA provided more useful guidance to clinicians. Here we retrospectively analyze 101 consecutive patients with brain metastases that had undergone WBRT, measured their survival in a nonprotocol setting and compared actual survival to that predicted by the RPA and GPA indices.
Materials & methods
Following study approval by our institutional review board, the charts of all consecutive brain metastasis patients treated with WBRT between August 2008 and September 2010 were reviewed. Reasons for exclusion from the study included primary brain tumors, <19 years old, diagnosis of multiple myeloma/leukemia/lymphoma, retreatment with WBRT and patients without evidence of parenchymal brain disease (i.e., leptomeningeal metastases, prophylactic treatment). The inclusion criteria were met by 101 patients. A retrospective chart review collected the data for calculating each patient's RPA and GPA (tables 1 & 2) as well as treatment details, including corticosteroid use and surgery and/or SRS. All patients had received MRIs. We based the number of brain metastases on the MRI report rather than review of MRI images. For 13 patients, KPS had to be retrospectively assigned from the radiation oncologist's consult note in cases where no KPS had been explicitly stated. For these, chart notes were examined for patient characteristics and exam findings to assign a KPS value. For five patients, KPS was converted from another performance status scale. To calculate survival time, the social security death 
statistical methods
Each patient was assigned an RPA and GPA score and was then grouped by those. Survival was calculated from the time of the WBRT consult date. MS was calculated using the Kaplan-Meier method. The associations of the categorical variables of RPA class and GPA grade with overall survival were examined with a log-rank test. Univariate Cox-proportional hazards models were done among patients with RPA II and also GPA 1.5-2.5 to investigate the association between sex, histology (NSCLC, melanoma, breast, SCLC, other), inclusion of surgery/SRS, number of CNS metastases (1, 2-3, >3), number of fractions (≤10 vs >10), age and KPS with overall survival. Multivariable Cox proportional hazards models were fit including all factors with univariate p-value <0.25. A backward selection approach was used to determine the final model.
Results
The mean (±SD) patient age was 57.4 (±10.6) years. Fifty-three percent were female (54 of 101). Forty-seven percent had NSCLC (47 of 101) and 12% each had melanoma and breast cancer (12 of 101 respectively). Patient and disease characteristics are shown in table 3. Of the 101 cases, the number that fit the RPA I, II and III classes were 8, 68 and 25 patients, respectively. The 68 RPA II patients in this study showed a median survival of 4.8 months (95% CI: 3.5-6.0 months). The predicted median survival of 4.2 months per the RTOG RPA falls within the 95% CI in our dataset.
All patients were also grouped according to the GPA index. This analysis showed that 2, 3, 61 and 35 patients resided in the 4 GPA classes; 3.5-4.0, 3.0, 1.5-2.5 and 0.0-1.0, respectively. For the 61 patients in the GPA 1.5-2.5, the median survival was 5.0 months (95% CI: 4.3-8.0). In this case, the predicted MS of 3.8 months per the GPA index is outside the 95% CI of the actual MS in our dataset. Survival varied significantly according to prognostic class. The survival of patients in RPA I versus II versus III was significantly different (MS 7.1, 4.8 and 2.4 months, respectively, p = 0.0016). Survival significantly differed by GPA grade (MS not yet achieved, 5.0 and 2.4 months for GPA grades 3.0-4.0, 1.5-2.5 and 0.0-1.0, respectively, p < 0.0001).
A total of 84 patients were in either the RPA II or the GPA 1.5-2.5 group. Forty-five patients were in both groups. Twenty-three patients were in the RPA II group only (four were GPA 3.0-4.0 and 19 were GPA 0.5-1.0) and 16 patients were in the GPA 1.5-2.5 group only (seven were RPA I and nine were RPA III). The RPA II only and GPA 1.5-2.5 only groups were similar on age, sex, histology, number of fractions and surgery (all p > 0.2). Patients who were only in the RPA II group had significantly higher KPS scores than patients who were only in the GPA 1.5-2.5 group (mean KPS: 76.7 [±7.9] vs 65.9 [±14.5], two-sample t-test p = 0.0131). Also, a greater proportion of RPA II only patients had more than three CNS metastases compared with patients who were only in the GPA 1.5-2.5 group (60.9 vs 18.8%, Mantel-Haenszel χ 2 p = 0.0106).
On univariate analysis in the RPA II group, increased survival was associated with being younger, having better KPS, female, treated with >10 fractions and undergoing surgery/SRS. In the GPA 1.5-2.5 group, having better KPS, being treated with >10 fractions and undergoing surgery/SRS were associated with significantly longer survival (table 4). Comparing RPA to the DS-GPA DS-GPA is better for stratifying to treatment types [25] BSBM: Basic System for brain metastases; DS-GPA: Diagnosis specific-GPA; GGS: Golden On multivariable analysis among RPA II patients, receiving >10 fractions and undergoing surgery/SRS were significantly associated with increased survival. Patients receiving ≤10 fractions had an hazard ratio (HR) of 2.45 (95% CI: 1.35-4.44) with increased risk of death compared with patients receiving >10 fractions (p = 0.0033). Patients who did not undergo surgery/SRS had an HR of 4.76 (95% CI: 2.28-9.95) with increased risk of death compared with patients who did undergo surgery/SRS (p < 0.0001). Among patients with GPA 1.5-2.5, better KPS and undergoing surgery/SRS were significantly associated with increased survival on multivariable analysis. Every 5-point decrease in KPS was associated with an HR of 1.20 for an increase in risk of death (95% CI: 1.07-1.35; p = 0.0020). Patients who did not undergo surgery/SRS had an HR of 2.78 (95% CI: 1.44-5.35) with increased risk of death compared with patients who did undergo surgery/SRS (p = 0.0022). However, number of fractions received was not statistically significant in the final multivariable model for patients in the GPA 1.5-2.5 group. If number of fractions is included in the model, along with KPS and surgery/SRS, the hazard ratio is 1.63 (95% CI: 0.88-3.01; p = 0.1192).
Discussion
Our data show that all moderate prognosis patients who received surgery or SRS tended to have a survival advantage versus those who did not. This finding is well supported in the literature and is understood to be due more to patient selection than to the treatment choice [15] [16] [17] .
Our analysis found that decreasing KPS was a hazard to survival for patients in the GPA 1.5-2.5 group, but not for patients in the RPA II group. This is likely because all patients in the RPA II category must have a relatively tight window of possible KPS values with a KPS ≥70. In the GPA 1.5 to 2.5 group KPS (a known independent predictor of survival) can be variable anywhere from 10 to 100 based on how the other three patient characteristics compromising the GPA are scored (tables 1 & 2) . Therefore, by definition of how the GPA is calculated, a continuum of patient outcomes in part related to the patient's KPS could be observed.
In the patients studied, RPA class and GPA scores were retrospectively assigned for this analysis. At the time of consultation, clinicians prescribed more or less aggressive WBRT fractionation schedules based on perceived prognosis. Patients assigned to the intermediate risk group with the RPA have a survival advantage with more aggressive WBRT fractionation (>10), but no such advantage was seen in the GPA intermediate risk group. As the number of treatment fractions should not be part of a prognostic system for estimating survival, this finding may indicate that the GPA is more helpful than the RPA for guiding clinicians' treatment decisions for moderate prognosis patients. There is perhaps too much variability in prognosis within the 'catch all' RPA II subgroup, leaving room for MS to be affected by more or less aggressive treatment decisions. The GPA is more granular by nature and does not seem to have this drawback.
Multiple prognostic indices exist for patients with brain metastases. We evaluated the RPA and the GPA, but some other commonly employed indices are: the DS-GPA, Score Index for Radiosurgery (SIR), Basic System for Brain Metastases (BSBM), RADES, Rotterdam score (RDAM) and Golden Grading System (GGS) [2, 4, 5, [18] [19] [20] [21] [22] . table 5 lists the factors considered when employing these prognostic guides. The impetus for our study was our desire to help select the most appropriate treatment for our patients. Our dilemma was in selecting the most reliable, easy to use prognostic guideline. Several recent studies have been published with this same goal in mind (table 6) [14, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] .
The DS-GPA [28, 29] has proved to be more granular than previous systems, but our population did not have enough patients of varying histologies to evaluate prognosis based on histology. A limitation of this study was a lack of power to find significance in survival between histologic subtypes, so in our analysis we chose to use the GPA as initially described. Although DS-GPA is the most recent system used for prognostication, the RPA and GPA are still being used in the radiation oncology and neuro-oncology communities. The GPA has also been validated to be a useful prognostic system [31] and compared with DS-GPA, the GPA is more user friendly. Future studies validating the DS-GPA against the GPA with larger groups of patients are warranted.
While our dataset is small and this is a singleinstitution retrospective study, our analysis contributes to the recently published body of work directed at finding a better prognostic definition for a sometimes difficult to assess population of patients. The volume of recent publications on this topic highlights the need among clinicians for better guidance when selecting treatment options for patients with metastatic brain disease when prognosis is unclear. Prospective studies are needed to better evaluate the ability of a prognostic index to guide treatment and accurately predict MS, quality of life and local control based on patient characteristics. Considering our results and our interpretation of the recent literature on this topic, the GPA (and, by extension, the DS-GPA) seems to be a reasonable prognostic index to bring forward into future prospective studies.
conclusion
The objective of this study was to evaluate whether the GPA or the RPA provided more useful guidance to clinicians for estimating survival in patients with brain metastases who have moderate prognosis. Our analysis compares the two indices' moderate prognosis groups because optimal treatment for these patients (RPA II or GPA 1.5-2.5) can be unclear. Better prognosis patients are often prescribed longer schedules of whole brain radiation. The RPA II and GPA 1.5-2.5 have similar predicted median survivals (4.2 and 3.8 months), and in our patient group, those scored by the RPA and assigned a longer radiation schedule had a survival advantage, while patients scored by the GPA did not. When prognostic factors are 'treatment related,' such as we found in our analysis of the RPA II, further stratification within the prognostic tool could be difficult. This could also indicate that the GPA is more clinically useful because it does not have this drawback, therefore leaving less room for a clinician's subjective assessment in choosing treatment.
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Papers of special note have been highlighted as: 
• The original Radiation Therapy Oncology
Group (RTOG) recursive partitioning analysis (RPA) was used for many years to guide treatment decisions. • The initial Graded Prognostic Assessment (GPA) system provided a more granular way to look at prognosis in patients with brain metastases.
